View Press Releases
Symbiosis Formally Presented with Prestigious King’s Award by Lord Lieutenant of Stirling and Falkirk
Symbiosis Formally Presented with Prestigious King’s Award by Lord Lieutenant of Stirling and Falkirk
Stirling, UK – 26 November 2025 – Symbiosis Pharmaceutical Services (Symbiosis), a global biopharmaceutical Contract Manufacturing Organisation (CMO) specialising in the sterile fill finish of injectable drug products, has been formally presented with a 2025 King’s Award for Enterprise in the International Trade category, the highest official accolade for British businesses.
The Lord-Lieutenant of Stirling and Falkirk, Colonel Charles Wallace, visited the company headquarters at Stirling Innovation Park to present the award on behalf of His Majesty the King. Also in attendance was the Lord Provost of the City of Stirling, Rosemary Fraser.
Symbiosis is one of only 197 UK businesses and one of only 11 Scottish companies to receive the prestigious award in 2025 recognising Symbiosis’ sustained and continual growth in international markets, including North America, Europe and the Asia-Pacific region.
The King’s Awards for Enterprise are granted annually by His Majesty King Charles III and are regarded as the pinnacle of British business achievement. Gaining the awards grants Symbiosis the right to display the King’s Award emblem for the next five years, symbolising excellence and credibility on the world stage.
During the presentation, the Lord-Lieutenant said the award represented recognition at the highest level. “It is a fantastic opportunity to present this honour on behalf of His Majesty the King,” he said. “The King’s Award for Enterprise reflects innovation, skill and determination, and Symbiosis demonstrates all these qualities. We are very fortunate to have a company of this calibre based here in Stirling, contributing to our local economy while excelling internationally.”
Colin MacKay, CEO of Symbiosis, welcomed the award and emphasised the collective effort behind the company’s success. “This recognition belongs to the entire team,” he said. “What motivates us every day is helping our clients develop medicines that make a meaningful difference to patients. We are proud to do that, and this award is an acknowledgement of many years of dedication and expertise across the business.”
The award highlights Symbiosis’ contribution to the UK’s global reputation for life science and manufacturing excellence. As the company expands its commercial scale manufacturing service offering at its new facility at Castle Business Park in Stirling, it remains committed to supporting global partners in the manufacture of complex injectable medicines that improve and save lives.
The King’s Award, previously known as The Queen’s Award for Enterprise, was renamed in 2023 to continue Queen Elizabeth II’s legacy of celebrating excellence in UK business.
ENDS
About Symbiosis Pharmaceutical Services:
Symbiosis Pharmaceutical Services (Symbiosis) is a world-class Contract Manufacturing Organisation (CMO) located in Stirling, UK, and is a specialist sterile GMP manufacturer of biopharmaceuticals for use in clinical trials and commercial sales globally. Symbiosis is MHRA-licensed and FDA-inspected and offers a range of services including the aseptic fill/finish of medicines into vials, analytical testing, QP release of product, inspection, labelling, packaging and GMP temperature-controlled storage and shipment of medicines.
The Symbiosis facility in Stirling, Scotland, was designed for biologic and small molecule pharmaceutical production to support biotechnology and pharmaceutical companies worldwide requiring sterile injectable pharmaceutical products manufactured in short timeframes for clinical trial use and commercial supply.
Regulatory compliance, technical capability and operational flexibility are core to the Symbiosis value proposition along with direct access to a highly experienced team of life science experts. By adding value directly to the new drug development projects and the commercial manufacturing supply chain requirements of its clients, Symbiosis has demonstrated consistent annual growth and built long-term relationships with its client base globally.
For more information on Symbiosis visit http://www.symbiosis-